Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population ; volume:25 ; number:1 ; day:12 ; month:9 ; year:2024 ; pages:1-13 ; date:12.2024
The journal of headache and pain ; 25, Heft 1 (12.9.2024), 1-13, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
An, Yu-Chin
Hung, Kuo-Sheng
Liang, Chih-Sung
Tsai, Chia-Kuang
Tsai, Chia-Lin
Chen, Sy-Jou
Lin, Yu-Kai
Lin, Guan-Yu
Yeh, Po-Kuan
Yang, Fu-Chi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-024-01850-y
- URN
-
urn:nbn:de:101:1-2411262127451.475247142457
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-15T07:21:01+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- An, Yu-Chin
- Hung, Kuo-Sheng
- Liang, Chih-Sung
- Tsai, Chia-Kuang
- Tsai, Chia-Lin
- Chen, Sy-Jou
- Lin, Yu-Kai
- Lin, Guan-Yu
- Yeh, Po-Kuan
- Yang, Fu-Chi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
CGRP and migraine: neurogenic inflammation revisited
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
CGRP and migraine: neurogenic inflammation revisited
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
CGRP and migraine: neurogenic inflammation revisited
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review